BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ouwerkerk W, Voors A, Anker S, Cleland J, Dickstein K, Filippatos G, van der Harst P, Hillege H, Lang C, ter Maaten J, Ng L, Ponikowski P, Samani N, van Veldhuisen D, Zannad F, Metra M, Zwinderman A. Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study. European Heart Journal 2017;38:1883-90. [DOI: 10.1093/eurheartj/ehx026] [Cited by in Crossref: 175] [Cited by in F6Publishing: 197] [Article Influence: 35.0] [Reference Citation Analysis]
Number Citing Articles
1 Soborun N, Müller M, Abdurashidova T, Tzimas G, Schukraft S, Lu H, Hugli O, Vollenweider P, Garnier A, Monney P, Hullin R. Already low drug dose antagonism of the renin-angiotensin aldosterone system decreases 1-year mortality and rehospitalization in old heart failure patients. Biomedicine & Pharmacotherapy 2022;154:113615. [DOI: 10.1016/j.biopha.2022.113615] [Reference Citation Analysis]
2 Hadidi SE, Bazan NS, Byrne S, Darweesh E, Bermingham M. Factors influencing prescribing by critical care physicians to heart failure patients in Egypt: a cross-sectional survey. Futur J Pharm Sci 2022;8. [DOI: 10.1186/s43094-022-00429-1] [Reference Citation Analysis]
3 Jarjour M, Leclerc J, Bouabdallaoui N, Ahnadi C, Brouillette D, de Denus S, Fortier A, Garceau P, Giraldeau G, Lepage S, Liszkowski M, O'Meara E, Parent MC, Racine N, Tremblay-Gravel M, White M, Rouleau JL, Ducharme A. Optimization of pharmacotherapies for ambulatory patients with heart failure and reduced ejection fraction is associated with improved outcomes. Int J Cardiol 2022:S0167-5273(22)01408-5. [PMID: 36174819 DOI: 10.1016/j.ijcard.2022.09.058] [Reference Citation Analysis]
4 Toto F, Salvioni E, Magrì D, Sciomer S, Piepoli M, Badagliacca R, Galotta A, Baracchini N, Paolillo S, Corrà U, Raimondo R, Lagioia R, Filardi PP, Iorio A, Senni M, Correale M, Cicoira M, Perna E, Metra M, Guazzi M, Limongelli G, Sinagra G, Parati G, Cattadori G, Bandera F, Bussotti M, Mapelli M, Cipriani M, Bonomi A, Cunha G, Re F, Vignati C, Garascia A, Lombardi C, Scardovi AB, Passantino A, Emdin M, Passino C, Santolamazza C, Girola D, Zaffalon D, Vizza D, De Martino F, Agostoni P; MECKI score research group. Does moderate hyperkalemia influence survival in HF? Insights from the MECKI score data base. Int J Cardiol 2022:S0167-5273(22)01340-7. [PMID: 36115445 DOI: 10.1016/j.ijcard.2022.09.030] [Reference Citation Analysis]
5 Ward T, Brown T, Lewis RD, Kliess MK, de Arellano AR, Quinn CM. The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland. Pharmacoecon Open 2022. [PMID: 35925491 DOI: 10.1007/s41669-022-00357-z] [Reference Citation Analysis]
6 Pandey A, Keshvani N, Wang TJ. Should Polypills Be Used for Heart Failure With Reduced Ejection Fraction? Circulation 2022;146:276-8. [PMID: 35877830 DOI: 10.1161/CIRCULATIONAHA.122.059661] [Reference Citation Analysis]
7 Dunlay SM, Killian JM, Roger VL, Schulte PJ, Blecker SB, Savitz ST, Redfield MM. Guideline Directed Medical Therapy in Newly Diagnosed Heart Failure with Reduced Ejection Fraction in the Community. J Card Fail 2022:S1071-9164(22)00648-0. [PMID: 35902033 DOI: 10.1016/j.cardfail.2022.07.047] [Reference Citation Analysis]
8 Tromp J, Voors AA. Heart failure medication: moving from evidence generation to implementation. Eur Heart J 2022:ehac272. [PMID: 35758247 DOI: 10.1093/eurheartj/ehac272] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Esteban-Fernández A, Ortiz Cortés C, López-Fernández S, Recio Mayoral A, Camacho Jurado FJ, Gómez Otero I, Molina M, Almenar Bonet L, López-Vilella R. Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life. ESC Heart Fail 2022. [PMID: 35748119 DOI: 10.1002/ehf2.13976] [Reference Citation Analysis]
10 Sato A, Nishimoto M. Clinical effect of nonsteroidal mineralocorticoid receptor (MR) antagonists in the treatment of diabetic kidney disease: expectations as a new therapeutic strategy. Hypertens Res 2022. [PMID: 35726084 DOI: 10.1038/s41440-022-00940-1] [Reference Citation Analysis]
11 Jan RK, Alsheikh-Ali A, Mulla AA, Sulaiman K, Panduranga P, Al-Mahmeed W, Bazargani N, Al-Suwaidi J, Al-Jarallah M, Al-Motarreb A, Salam A, Al-Zakwani I. Outcomes of guideline-based medical therapy in patients with acute heart failure and reduced left ventricular ejection fraction: Observations from the Gulf acute heart failure registry (Gulf CARE). Medicine (Baltimore) 2022;101:e29452. [PMID: 35687781 DOI: 10.1097/MD.0000000000029452] [Reference Citation Analysis]
12 Streng KW, Hillege HL, Ter Maaten JM, van Veldhuisen DJ, Dickstein K, Ng LL, Samani NJ, Metra M, Ponikowski P, Cleland JG, Anker SD, Romaine SPR, Damman K, van der Meer P, Lang CC, Voors AA. Clinical implications of low estimated protein intake in patients with heart failure. J Cachexia Sarcopenia Muscle 2022;13:1762-70. [PMID: 35426256 DOI: 10.1002/jcsm.12973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Israr MZ, Zhan H, Salzano A, Voors AA, Cleland JG, Anker SD, Metra M, van Veldhuisen DJ, Lang CC, Zannad F, Samani NJ, Ng LL, Suzuki T; BIOSTAT-CHF investigators (full author list as appendix). Surrogate markers of gut dysfunction are related to heart failure severity and outcome-from the BIOSTAT-CHF consortium. Am Heart J 2022;248:108-19. [PMID: 35278373 DOI: 10.1016/j.ahj.2022.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Pierce JB, Mentz RJ, Sun J, Alhanti B, Whellan DJ, Kraus WE, Piña IL, Fiuzat M, O'connor CM, Greene SJ. Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial. Journal of Cardiac Failure 2022. [DOI: 10.1016/j.cardfail.2022.05.010] [Reference Citation Analysis]
15 Pierce JB, Mentz RJ, Sun JL, Alhanti B, Whellan DJ, Kraus WE, Piña IL, Fiuzat M, O'Connor CM, Greene SJ. Titration of medical therapy and clinical outcomes among patients with heart failure with reduced ejection fraction: findings from the HF-ACTION trial. Am Heart J 2022:S0002-8703(22)00111-9. [PMID: 35640729 DOI: 10.1016/j.ahj.2022.05.018] [Reference Citation Analysis]
16 Baumhove L, Tromp J, Figarska S, van Essen BJ, Anker SD, Dickstein K, Cleland JG, Lang CC, Filippatos G, Ng LL, Samani NJ, Metra M, van Veldhuisen DJ, Lam CSP, Voors AA, van der Meer P. Heart failure with normal LVEF in BIOSTAT-CHF. Int J Cardiol 2022:S0167-5273(22)00765-3. [PMID: 35649488 DOI: 10.1016/j.ijcard.2022.05.054] [Reference Citation Analysis]
17 Greene SJ, Lautsch D, Gaggin HK, Djatche LM, Zhou M, Song Y, Signorovitch J, Stevenson AS, Blaustein RO, Butler J. Contemporary Outpatient Management of Patients with Worsening Heart Failure with Reduced Ejection Fraction: Rationale and Design of the CHART-HF Study. Am Heart J 2022:S0002-8703(22)00110-7. [PMID: 35640728 DOI: 10.1016/j.ahj.2022.05.016] [Reference Citation Analysis]
18 Herrmann EJ, Raghavan B, Eissing N, Fichtlscherer S, Hamm CW, Assmus B. Pulmonary Artery Pressure-Guided Telemonitoring Reduced Pulmonary Artery Pressure but Did Not Result in Higher Doses of Guideline-Directed Medical Therapy–Observations from an Advanced Elderly German Heart Failure Cohort. Life 2022;12:766. [DOI: 10.3390/life12050766] [Reference Citation Analysis]
19 Kawakubo Y, Shiraishi Y, Kohsaka S, Kohno T, Goda A, Nagatomo Y, Nishihata Y, Saji M, Takei M, Ikegami Y, Niimi N, Sandhu ATS, Nakano S, Yoshikawa T, Fukuda K; West Tokyo Heart Failure Registry. Potential association with malnutrition and allocation of combination medical therapies in hospitalized heart failure patients with reduced ejection fraction. Sci Rep 2022;12:8318. [PMID: 35585128 DOI: 10.1038/s41598-022-12357-4] [Reference Citation Analysis]
20 Milinković I, Polovina M, Coats AJ, Rosano GM, Seferović PM. Medical Treatment of Heart Failure with Reduced Ejection Fraction in the Elderly. Card Fail Rev 2022;8:e17. [DOI: 10.15420/cfr.2021.14] [Reference Citation Analysis]
21 Girerd N, Von Hunolstein J, Pellicori P, Bayés‐genís A, Jaarsma T, Lund LH, Bilbault P, Boivin J, Chouihed T, Costa J, Eicher J, Fall E, Kenizou D, Maillier B, Nazeyrollas P, Roul G, Zannad N, Rossignol P, Seronde M; EF‐HF Group. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. ESC Heart Failure. [DOI: 10.1002/ehf2.13929] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Davidson BT, Dunham S. The Perfect Storm. Critical Care Nursing Clinics of North America 2022. [DOI: 10.1016/j.cnc.2022.02.003] [Reference Citation Analysis]
23 Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, Filippatos GS, Inciardi RM, Lang CC, Lombardi CM, Ng LL, Ponikowski P, Samani NJ, Zannad F, van Veldhuisen DJ, Voors AA, Metra M. Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. Clin Res Cardiol 2022. [PMID: 35294624 DOI: 10.1007/s00392-022-01991-7] [Reference Citation Analysis]
24 Nakayama T, Morimoto K, Uchiyama K, Kusahana E, Washida N, Azegami T, Kanda T, Yoshida T, Itoh H. Effects of renin-angiotensin system inhibitors on the incidence of unplanned dialysis. Hypertens Res. [DOI: 10.1038/s41440-022-00877-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Beldhuis IE, Lam CSP, Testani JM, Voors AA, Van Spall HGC, Ter Maaten JM, Damman K. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation 2022;145:693-712. [PMID: 35226558 DOI: 10.1161/CIRCULATIONAHA.121.052792] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
26 Vishram-Nielsen JKK, Tomasoni D, Gustafsson F, Metra M. Contemporary Drug Treatment of Advanced Heart Failure with Reduced Ejection Fraction. Drugs 2022. [PMID: 35113350 DOI: 10.1007/s40265-021-01666-z] [Reference Citation Analysis]
27 Oyanguren J, Díaz-molina B, Lekuona I, González-costello J, López-fernández S, García-pinilla JM, Garcia-garrido L, López-moyano G, Manito N, Cobo-marcos M, Nebot-margalef M, Latorre-garcía P, Arana-arri E, Pérez-fernández S, Torcal-laguna J. Diferencias de género en la titulación de fármacos de pacientes con insuficiencia cardiaca y fracción de eyección reducida del ensayo ETIFIC. Revista Española de Cardiología 2022. [DOI: 10.1016/j.recesp.2021.10.022] [Reference Citation Analysis]
28 Brownell NK, Ziaeian B, Fonarow GC. The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction. Card Fail Rev 2021;7:e18. [PMID: 34950508 DOI: 10.15420/cfr.2021.18] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
29 Piña IL. SGLT2 inhibitors: the story continues to unfold. Eur Heart J 2021;42:4902-4. [PMID: 34423356 DOI: 10.1093/eurheartj/ehab561] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Bahouth F, Elias A, Ghersin I, Khoury E, Bar O, Sholy H, Khoury J, Azzam ZS. The prognostic value of heart rate at discharge in acute decompensation of heart failure with reduced ejection fraction. ESC Heart Fail 2021. [PMID: 34821080 DOI: 10.1002/ehf2.13710] [Reference Citation Analysis]
31 James G, Kim J, Mellström C, Ford KL, Jenkins NC, Tsang C, Evans M, Mcewan P. Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. Clinical Kidney Journal 2021. [DOI: 10.1093/ckj/sfab225] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Butler J, Anker SD, Siddiqi TJ, Coats AJS, Dorigotti F, Filippatos G, Friede T, Göhring UM, Kosiborod MN, Lund LH, Metra M, Moreno Quinn C, Piña IL, Pinto FJ, Rossignol P, Szecsödy P, Van Der Meer P, Weir M, Pitt B. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. Eur J Heart Fail 2021. [PMID: 34800079 DOI: 10.1002/ejhf.2386] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
33 Ahmed KO, Taj Eldin I, Yousif M, Albarraq AA, Yousef BA, Ahmed N, Babiker A. Clinical Pharmacist's Intervention to Improve Medication Titration for Heart Failure: First Experience from Sudan. Integr Pharm Res Pract 2021;10:135-43. [PMID: 34796093 DOI: 10.2147/IPRP.S341621] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
34 Rea F, Iorio A, Barbati G, Bessi R, Castrichini M, Nuzzi V, Scagnetto A, Senni M, Corrao G, Sinagra G, Di Lenarda A. Patient adherence to drug treatment in a community based-sample of patients with chronic heart failure. Int J Cardiol 2021:S0167-5273(21)01788-5. [PMID: 34801616 DOI: 10.1016/j.ijcard.2021.11.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
35 Olry de Labry Lima A, Díaz Castro Ó, Romero-Requena JM, García Díaz-Guerra MLR, Arroyo Pineda V, de la Hija Díaz MB, Ascanio M, Darbà J, Cruzado JM. Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain. Clin Kidney J 2021;14:2391-400. [PMID: 34754435 DOI: 10.1093/ckj/sfab076] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Guseynova ET, Kutishenko NP, Lukina YV, Tolpygina SN, Voronina VP, Blagodatskih SV, Drapkina OM, Martsevich SY. Study of the Quality of Medical Therapy and Adherence in Patients with Chronic Heart Failure (According to the COMPLIANCE Study). Racionalʹnaâ farmakoterapiâ v kardiologii 2021;17:738-42. [DOI: 10.20996/1819-6446-2021-10-10] [Reference Citation Analysis]
37 Santema BT, Arita VA, Sama IE, Kloosterman M, van den Berg MP, Nienhuis HLA, Van Gelder IC, van der Meer P, Zannad F, Metra M, Ter Maaten JM, Cleland JG, Ng LL, Anker SD, Lang CC, Samani NJ, Dickstein K, Filippatos G, van Veldhuisen DJ, Lam CSP, Rienstra M, Voors AA. Pathophysiological pathways in patients with heart failure and atrial fibrillation. Cardiovasc Res 2021:cvab331. [PMID: 34687289 DOI: 10.1093/cvr/cvab331] [Reference Citation Analysis]
38 Logeart D, Berthelot E, Bihry N, Eschalier R, Salvat M, Garcon P, Eicher JC, Cohen A, Tartiere JM, Samadi A, Donal E, deGroote P, Mewton N, Mansencal N, Raphael P, Ghanem N, Seronde MF, Chavelas C, Rosamel Y, Beauvais F, Kevorkian JP, Diallo A, Vicaut E, Isnard R. Early and short-term intensive management after discharge for patients hospitalized with acute heart failure: a randomized study (ECAD-HF). Eur J Heart Fail 2021. [PMID: 34628697 DOI: 10.1002/ejhf.2357] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Greene SJ, Butler J, Hellkamp AS, Spertus JA, Vaduganathan M, DeVore AD, Albert NM, Herbert Patterson J, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry. J Card Fail 2021:S1071-9164(21)00393-6. [PMID: 34793971 DOI: 10.1016/j.cardfail.2021.08.023] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
40 Masarone D, Martucci ML, Errigo V, Pacileo G. The Use of β-Blockers in Heart Failure with Reduced Ejection Fraction. J Cardiovasc Dev Dis 2021;8:101. [PMID: 34564119 DOI: 10.3390/jcdd8090101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
41 Ghys LF, Martens P, Heggermont WA, Gabriel L, Heyse A, Troisfontaines P, Maris M. The in- and out-of-hospital management of HF patients: results from a nationwide Belgian survey. Acta Cardiol 2021;76:632-41. [PMID: 32507048 DOI: 10.1080/00015385.2020.1765105] [Reference Citation Analysis]
42 Sousa LS, Nascimento FDA, Rocha J, Rocha-parise M. Cardioprotective Effects of Sodium-glucose Cotransporter 2 Inhibitors Regardless of Type 2 Diabetes Mellitus: A Meta-analysis. International Journal of Cardiovascular Sciences 2021. [DOI: 10.36660/ijcs.20200339] [Reference Citation Analysis]
43 Sabouret P, Attias D, Beauvais C, Berthelot E, Bouleti C, Gibault Genty G, Galat A, Hanon O, Hulot JS, Isnard R, Jourdain P, Lamblin N, Lebreton G, Lellouche N, Logeart D, Meune C, Pezel T, Damy T. Diagnosis and management of heart failure from hospital admission to discharge: A practical expert guidance. Ann Cardiol Angeiol (Paris) 2021:S0003-3928(21)00068-8. [PMID: 34274113 DOI: 10.1016/j.ancard.2021.05.004] [Reference Citation Analysis]
44 Fine NM, Walsh MN. Juggling While Dancing: The Complex Medical Management of Heart Failure With Reduced Ejection Fraction. JACC Case Rep 2021;3:1077-80. [PMID: 34317688 DOI: 10.1016/j.jaccas.2021.05.015] [Reference Citation Analysis]
45 Hu J, Wu Y, Zhou X, Wang X, Jiang W, Huo J, Shan Q. Beneficial Effects of Sacubitril/Valsartan at Low Doses in an Asian Real-World Heart Failure Population. J Cardiovasc Pharmacol 2020;76:445-51. [PMID: 33030857 DOI: 10.1097/FJC.0000000000000873] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
46 Pagnesi M, Adamo M, Sama IE, Anker SD, Cleland JG, Dickstein K, Filippatos GS, Lang CC, Ng LL, Ponikowski P, Ravera A, Samani NJ, Zannad F, van Veldhuisen DJ, Voors AA, Metra M. Impact of mitral regurgitation in patients with worsening heart failure: insights from BIOSTAT-CHF. Eur J Heart Fail 2021. [PMID: 34164895 DOI: 10.1002/ejhf.2276] [Cited by in Crossref: 2] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
47 Savarese G, Bodegard J, Norhammar A, Sartipy P, Thuresson M, Cowie MR, Fonarow GC, Vaduganathan M, Coats AJS. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden). Eur J Heart Fail 2021. [PMID: 34132001 DOI: 10.1002/ejhf.2271] [Cited by in Crossref: 4] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
48 Nauta JF, Santema BT, van der Wal MHL, Koops A, Warink-Riemersma J, van Dijk K, Inkelaar F, Prückl S, Suwijn J, van Deursen VM, Meijers WC, Coster J, Westenbrink BD, de Boer RA, Hummel Y, van Melle J, van Veldhuisen DJ, van der Meer P, Voors AA. Improvement in left ventricular ejection fraction after pharmacological up-titration in new-onset heart failure with reduced ejection fraction. Neth Heart J 2021;29:383-93. [PMID: 34125353 DOI: 10.1007/s12471-021-01591-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Gysan DB, Pfister R, Bansmann M, Kalkan A, Latz V, Scholl M, Perings S. Herzinsuffizienzbehandlung in Integrierten Versorgungsmodellen nach § 140 SGB V. Aktuelle Kardiologie 2021;10:240-4. [DOI: 10.1055/a-1429-2610] [Reference Citation Analysis]
50 Bistola V, Simitsis P, Parissis J, Ouwerkerk W, van Veldhuisen DJ, Cleland JG, Anker SD, Samani NJ, Metra M, Zannad F, Polyzogopoulou E, Keramida K, Farmakis D, Voors AA, Filippatos G. Association between up-titration of medical therapy and total hospitalizations and mortality in patients with recent worsening heart failure across the ejection fraction spectrum. Eur J Heart Fail 2021;23:1170-81. [PMID: 33998113 DOI: 10.1002/ejhf.2219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Ismail U, Sidhu K, Zieroth S. Hyperkalaemia in Heart Failure. Card Fail Rev 2021;7:e10. [PMID: 34094588 DOI: 10.15420/cfr.2020.29] [Reference Citation Analysis]
52 Voors AA, Mulder H, Reyes E, Cowie MR, Lassus J, Hernandez AF, Ezekowitz JA, Butler J, O'Connor CM, Koglin J, Lam CSP, Pieske B, Roessig L, Ponikowski P, Anstrom KJ, Armstrong PW; VICTORIA Study Group. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial. Eur J Heart Fail 2021;23:1313-21. [PMID: 33999486 DOI: 10.1002/ejhf.2221] [Cited by in Crossref: 2] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
53 Oyanguren J, Garcia-garrido L, Nebot-margalef M, Latorre-garcía P, Torcal-laguna J, Comín-colet J, Roure J, González-costello J, Manito N, García-pinilla JM, Sánchez-paule Y, Varela-román A, Moure M, Segovia-cubero J, Soria T, Arana-arri E, Lekuona I. No inferioridad de la titulación de enfermera de insuficiencia cardiaca en comparación con la de cardiólogo de insuficiencia cardiaca. Ensayo aleatorizado multicéntrico ETIFIC. Revista Española de Cardiología 2021;74:533-43. [DOI: 10.1016/j.recesp.2020.04.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
54 Ferreira JP, Konstam MA, McMurray JJV, Butler J, Girerd N, Rossignol P, Sharma A, Voors AA, Lam CSP, Packer M, Zannad F. Dosing of losartan in men versus women with heart failure with reduced ejection fraction: the HEAAL trial. Eur J Heart Fail 2021. [PMID: 34050594 DOI: 10.1002/ejhf.2255] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
55 Ameri P, Bertero E, Maack C, Teerlink JR, Rosano G, Metra M. Medical treatment of heart failure with reduced ejection fraction: the dawn of a new era of personalized treatment? Eur Heart J Cardiovasc Pharmacother 2021:pvab033. [PMID: 34037742 DOI: 10.1093/ehjcvp/pvab033] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
56 Wang K, Youngson E, Bakal JA, Thomas J, McAlister FA, Oudit GY. Cardiac reverse remodelling and health status in patients with chronic heart failure. ESC Heart Fail 2021;8:3106-18. [PMID: 34002942 DOI: 10.1002/ehf2.13417] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
57 Kobayashi M, Voors AA, Ouwerkerk W, Duarte K, Girerd N, Rossignol P, Metra M, Lang CC, Ng LL, Filippatos G, Dickstein K, van Veldhuisen DJ, Zannad F, Ferreira JP. Perceived risk profile and treatment optimization in heart failure: an analysis from BIOlogy Study to TAilored Treatment in chronic heart failure. Clin Cardiol 2021;44:780-8. [PMID: 33960439 DOI: 10.1002/clc.23576] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
58 Langhammer R, Wachter R. [New treatment options of heart failure with reduced ejection fraction]. MMW Fortschr Med 2021;163:28-37. [PMID: 33950447 DOI: 10.1007/s15006-021-9806-x] [Reference Citation Analysis]
59 Paolillo S, Dell'Aversana S, Esposito I, Poccia A, Perrone Filardi P. The use of β-blockers in patients with heart failure and comorbidities: Doubts, certainties and unsolved issues. Eur J Intern Med 2021;88:9-14. [PMID: 33941435 DOI: 10.1016/j.ejim.2021.03.035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
60 Hasin T, Davarashvili I, Michowitz Y, Farkash R, Presman H, Glikson M, Rav-Acha M. Association of Guideline-Based Medical Therapy with Malignant Arrhythmias and Mortality among Heart Failure Patients Implanted with Cardioverter Defibrillator (ICD) or Cardiac Resynchronization-Defibrillator Device (CRTD). J Clin Med 2021;10:1753. [PMID: 33920719 DOI: 10.3390/jcm10081753] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Emmens JE, Jia C, Ng LL, van Veldhuisen DJ, Dickstein K, Anker SD, Lang CC, Filippatos G, Cleland JGF, Metra M, Voors AA, de Boer RA, Tietge UJF. Impaired High-Density Lipoprotein Function in Patients With Heart Failure. J Am Heart Assoc 2021;10:e019123. [PMID: 33870728 DOI: 10.1161/JAHA.120.019123] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
62 Lam CSP, Wood R, Vaduganathan M, Bueno H, Chin A, Luporini Saraiva G, Sörstadius E, Tritton T, Thomas J, Qin L. Contemporary economic burden in a real-world heart failure population with Commercial and Medicare supplemental plans. Clin Cardiol 2021;44:646-55. [PMID: 33704817 DOI: 10.1002/clc.23585] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Carubelli V, Lombardi C, Specchia C, Peveri G, Oriecuia C, Tomasoni D, Di Pasquale M, Inciardi R, Garrafa E, Metra M. Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta-blockers in patients hospitalized for acute heart failure. ESC Heart Fail 2021;8:1944-53. [PMID: 33660949 DOI: 10.1002/ehf2.13223] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
64 McCullough PA, Rahimi G, Tecson KM. Ambulatory Worsening of Renal Function in Heart Failure With Preserved Ejection Fraction. J Am Coll Cardiol 2021;77:1222-4. [PMID: 33663740 DOI: 10.1016/j.jacc.2021.01.007] [Reference Citation Analysis]
65 Parajuli DR, Shakib S, Eng-Frost J, McKinnon RA, Caughey GE, Whitehead D. Evaluation of the prescribing practice of guideline-directed medical therapy among ambulatory chronic heart failure patients. BMC Cardiovasc Disord 2021;21:104. [PMID: 33602125 DOI: 10.1186/s12872-021-01868-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Cowie MR, Schöpe J, Wagenpfeil S, Tavazzi L, Böhm M, Ponikowski P, Anker SD, Filippatos GS, Komajda M; QUALIFY Investigators. Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. ESC Heart Fail 2021;8:861-71. [PMID: 33569926 DOI: 10.1002/ehf2.13237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
67 Gill H, Chehab O, Allen C, Patterson T, Redwood S, Rajani R, Prendergast B. The advantages, pitfalls and limitations of guideline-directed medical therapy in patients with valvular heart disease. Eur J Heart Fail 2021;23:1325-33. [PMID: 33421239 DOI: 10.1002/ejhf.2097] [Reference Citation Analysis]
68 Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, Filippatos G, Hauske SJ, Brueckmann M, Pfarr E, Schnee J, Wanner C, Packer M. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Circulation 2021;143:310-21. [PMID: 33095032 DOI: 10.1161/CIRCULATIONAHA.120.051685] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
69 Cardoso J, Espíndola MD, Cunha M, Netto E, Cardoso C, Novaes M, Del Carlo CH, Brancalhão E, Name AL, Barretto ACP. Is Current Drug Therapy for Heart Failure Sufficient to Control Heart Rate of Patients? Arq Bras Cardiol 2020;115:1063-9. [PMID: 33470302 DOI: 10.36660/abc.20190090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
70 Greene SJ, Tan X, Yeh YC, Bernauer M, Zaidi O, Yang M, Butler J. Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. Heart Fail Rev 2021. [PMID: 33471236 DOI: 10.1007/s10741-021-10077-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Miller RJH, Howlett JG, Fine NM. A Novel Approach to Medical Management of Heart Failure With Reduced Ejection Fraction. Can J Cardiol 2021;37:632-43. [PMID: 33453357 DOI: 10.1016/j.cjca.2020.12.028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
72 Adler J, Gerhardt F, Wissmüller M, Adler C, Baldus S, Rosenkranz S. Pulmonary hypertension associated with left-sided heart failure. Curr Opin Cardiol 2020;35:610-9. [PMID: 32969856 DOI: 10.1097/HCO.0000000000000791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
73 El Hadidi S, Vaughan C, Kerins D, Byrne S, Darweesh E, Bermingham M. Guideline-led prescribing to ambulatory heart failure patients in a cardiology outpatient service. Int J Clin Pharm 2021;43:1082-9. [PMID: 33411177 DOI: 10.1007/s11096-020-01220-z] [Reference Citation Analysis]
74 Verhestraeten C, Weijers G, Debleu D, Ciarka A, Goethals M, Droogmans S, Maris M. Diagnosis, treatment, and follow-up of heart failure patients by general practitioners: A Delphi consensus statement. PLoS One 2020;15:e0244485. [PMID: 33382755 DOI: 10.1371/journal.pone.0244485] [Reference Citation Analysis]
75 Russian Society of Cardiology (RSC) (. 2020 Clinical practice guidelines for Chronic heart failure. Russ J Cardiol 2020;25:4083. [DOI: 10.15829/1560-4071-2020-4083] [Cited by in Crossref: 63] [Cited by in F6Publishing: 19] [Article Influence: 31.5] [Reference Citation Analysis]
76 van der Wal HH, Grote Beverborg N, Dickstein K, Anker SD, Lang CC, Ng LL, van Veldhuisen DJ, Voors AA, van der Meer P. Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use. Eur Heart J 2019;40:3616-25. [PMID: 31556953 DOI: 10.1093/eurheartj/ehz680] [Cited by in Crossref: 23] [Cited by in F6Publishing: 38] [Article Influence: 11.5] [Reference Citation Analysis]
77 Volterrani M, Perrone V, Sangiorgi D, Giacomini E, Iellamo F, Degli Esposti L; on the behalf of a LHUs Study Group (see Appendix). Effects of hyperkalaemia and non-adherence to renin-angiotensin-aldosterone system inhibitor therapy in patients with heart failure in Italy: a propensity-matched study. Eur J Heart Fail 2020;22:2049-55. [PMID: 33459467 DOI: 10.1002/ejhf.2024] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
78 Senninger L, Abensur Vuillaume L, Frimat L, Girerd N, Lamiral Z, Rossignol P, Boivin JM. Dyskalemia: a management problem for students. Fundam Clin Pharmacol 2021;35:473-84. [PMID: 33098726 DOI: 10.1111/fcp.12621] [Reference Citation Analysis]
79 Zannad F, Ferreira JP, Pocock SJ, Zeller C, Anker SD, Butler J, Filippatos G, Hauske SJ, Brueckmann M, Pfarr E, Schnee J, Wanner C, Packer M. Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced. Circulation 2021;143:310-21. [PMID: 33095032 DOI: 10.1161/CIRCULATIONAHA.120.051685] [Cited by in Crossref: 26] [Cited by in F6Publishing: 57] [Article Influence: 13.0] [Reference Citation Analysis]
80 Hung CL, Chao TF, Su CH, Liao JN, Sung KT, Yeh HI, Chiang CE. Income level and outcomes in patients with heart failure with universal health coverage. Heart 2021;107:208-16. [PMID: 33082175 DOI: 10.1136/heartjnl-2020-316793] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
81 Yao Y, Zhang R, Zhang Q, Zhao X, Zhang J. Does higher SBP at discharge explain better outcomes in non-heart failure with reduced ejection fraction patients? Insights from Fuwai Hospital. J Hypertens 2021;39:356-66. [PMID: 33031173 DOI: 10.1097/HJH.0000000000002633] [Reference Citation Analysis]
82 Mullasari A; PROFICIENT investigators. Efficacy and Safety of Ivabradine Once-Daily Prolonged-Release versus Twice-Daily Immediate-Release Formulation in Patients with Stable Chronic Heart Failure with Systolic Dysfunction: A Randomized, Double-Blind, Phase 3 Non-Inferiority (PROFICIENT) Study. Cardiol Ther 2020;9:505-21. [PMID: 33006062 DOI: 10.1007/s40119-020-00200-8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
83 Tereshchenko SN, Zhirov IV, Uskach TM, Saidova MA, Golitsyn SP, Gupalo EM, Nasonova SN, Narusov OY, Safiullina AA, Tereshchenko AS, Stukalova OV. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). Evrazijskij kardiologičeskij žurnal 2020. [DOI: 10.38109/2225-1685-2020-3-6-76] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Punnoose LR, Lindenfeld J. Sex-specific differences in access and response to medical and device therapies in heart failure: State of the art. Prog Cardiovasc Dis 2020;63:640-8. [PMID: 32987026 DOI: 10.1016/j.pcad.2020.09.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
85 Niriayo YL, Asgedom SW, Demoz GT, Gidey K. Treatment optimization of beta-blockers in chronic heart failure therapy. Sci Rep 2020;10:15903. [PMID: 32981932 DOI: 10.1038/s41598-020-72836-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
86 Berliner D, Bauersachs J. New drugs: big changes in conservative heart failure therapy? Eur J Cardiothorac Surg. 2019;55:i3-i10. [PMID: 31106335 DOI: 10.1093/ejcts/ezy421] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
87 Berliner D, Hänselmann A, Bauersachs J. The Treatment of Heart Failure with Reduced Ejection Fraction. Dtsch Arztebl Int 2020;117:376-86. [PMID: 32843138 DOI: 10.3238/arztebl.2020.0376] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
88 El Hadidi S, Samir Bazan N, Byrne S, Darweesh E, Bermingham M. Heart Failure Prescribing Quality at Discharge from a Critical Care Unit in Egypt: The Impact of Multidisciplinary Care. Pharmacy (Basel) 2020;8:E159. [PMID: 32882858 DOI: 10.3390/pharmacy8030159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
89 Fonseca C, Brito D, Branco P, Frazão JM, Silva-Cardoso J, Bettencourt P. Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: A systematic review. Rev Port Cardiol (Engl Ed) 2020;39:517-41. [PMID: 32868174 DOI: 10.1016/j.repc.2020.03.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
90 Guggilla RK, Sowa PM, Jamiolkowski J, Sinnadurai S, Amin A, Kaminski KA. Effects of neurohormonal antagonists on blood pressure in patients with heart failure with reduced ejection fraction (HFrEF): a systematic review protocol. Syst Rev 2020;9:194. [PMID: 32838804 DOI: 10.1186/s13643-020-01452-0] [Reference Citation Analysis]
91 Migliavaca CB, Stein C, Colpani V, Eibel B, Bgeginski R, Simões MV, Rohde LE, Falavigna M. High-dose versus low-dose angiotensin converting enzyme inhibitors in heart failure: systematic review and meta-analysis. Open Heart 2020;7:e001228. [PMID: 32820054 DOI: 10.1136/openhrt-2019-001228] [Reference Citation Analysis]
92 Jarjour M, Henri C, de Denus S, Fortier A, Bouabdallaoui N, Nigam A, O'Meara E, Ahnadi C, White M, Garceau P, Racine N, Parent MC, Liszkowski M, Giraldeau G, Rouleau JL, Ducharme A. Care Gaps in Adherence to Heart Failure Guidelines: Clinical Inertia or Physiological Limitations? JACC Heart Fail 2020;8:725-38. [PMID: 32800509 DOI: 10.1016/j.jchf.2020.04.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
93 Kalogeropoulos AP, Simitsis P, Skopicki HA. Secrets of spironolactone: continuing insights from TOPCAT Americas. Eur J Heart Fail 2020;22:1625-7. [PMID: 32628354 DOI: 10.1002/ejhf.1959] [Reference Citation Analysis]
94 Gras M, Bisson A, Bodin A, Herbert J, Babuty D, Pierre B, Clementy N, Fauchier L. Mortality and cardiac resynchronization therapy with or without defibrillation in primary prevention. Europace 2020;22:1224-33. [PMID: 32594143 DOI: 10.1093/europace/euaa096] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
95 Keramida K, Filippatos G. Heart failure guidelines implementation: Lifting barriers using registries and networks. Anatol J Cardiol 2020;24:41-2. [PMID: 32628142 DOI: 10.14744/AnatolJCardiol.2020.62747] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
96 Mapelli M, Salvioni E, de Martino F, Mattavelli I, Bonomi A, Sassi V, Gugliandolo P, Vignati C, Magini A, Rovai S, Paolillo S, Agostoni P. Sacubitril/valsartan use in a real-world population of patients with heart failure and reduced ejection fraction. Journal of Cardiovascular Medicine 2020;21:882-8. [DOI: 10.2459/jcm.0000000000001018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
97 Mewton N, Girerd N, Boffa JJ, Courivaud C, Isnard R, Juillard L, Lamblin N, Legrand M, Logeart D, Mariat C, Meune E, Sabouret P, Sebbag L, Rossignol P. Practical management of worsening renal function in outpatients with heart failure and reduced ejection fraction: Statement from a panel of multidisciplinary experts and the Heart Failure Working Group of the French Society of Cardiology. Arch Cardiovasc Dis 2020;113:660-70. [PMID: 32660835 DOI: 10.1016/j.acvd.2020.03.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
98 Fernández-vázquez D, Ferrero-gregori A, Álvarez-garcía J, Gómez-otero I, Vázquez R, Delgado Jiménez J, Worner Diz F, Bardají A, García-pavía P, Bayés-genís A, González-juanatey JR, Cinca J, Pascual Figal DA. Cambio en la causa de muerte e influencia de la mejora terapéutica con el tiempo en pacientes con insuficiencia cardiaca y fracción de eyección reducida. Revista Española de Cardiología 2020;73:561-8. [DOI: 10.1016/j.recesp.2019.09.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
99 Bots SH, Groepenhoff F, Eikendal ALM, Tannenbaum C, Rochon PA, Regitz-Zagrosek V, Miller VM, Day D, Asselbergs FW, den Ruijter HM. Adverse Drug Reactions to Guideline-Recommended Heart Failure Drugs in Women: A Systematic Review of the Literature. JACC Heart Fail 2019;7:258-66. [PMID: 30819382 DOI: 10.1016/j.jchf.2019.01.009] [Cited by in Crossref: 25] [Cited by in F6Publishing: 33] [Article Influence: 12.5] [Reference Citation Analysis]
100 Abensur Vuillaume L, Rossignol P, Lamiral Z, Girerd N, Boivin JM. Hyperkalaemia and hypokalaemia outpatient management: a survey of 500 French general practitioners. ESC Heart Fail 2020;7:2042-50. [PMID: 32602236 DOI: 10.1002/ehf2.12834] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
101 Oyanguren J, Garcia-Garrido L, Nebot-Margalef M, Latorre-García P, Torcal-Laguna J, Comín-Colet J, Roure J, González-Costello J, Manito N, García-Pinilla JM, Sánchez-Paule Y, Varela-Román A, Moure M, Segovia-Cubero J, Soria T, Arana-Arri E, Lekuona I; Steering Committee on behalf of the ETIFIC research team group. Noninferiority of heart failure nurse titration versus heart failure cardiologist titration. ETIFIC multicenter randomized trial. Rev Esp Cardiol (Engl Ed) 2021;74:533-43. [PMID: 32591295 DOI: 10.1016/j.rec.2020.04.016] [Reference Citation Analysis]
102 Lombardi C, Peveri G, Cani D, Latta F, Bonelli A, Tomasoni D, Sbolli M, Ravera A, Carubelli V, Saccani N, Specchia C, Metra M. In-hospital and long-term mortality for acute heart failure: analysis at the time of admission to the emergency department. ESC Heart Fail 2020;7:2650-61. [PMID: 32588981 DOI: 10.1002/ehf2.12847] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
103 Ouwerkerk W, Teng TK, Tromp J, Tay WT, Cleland JG, Veldhuisen DJ, Dickstein K, Ng LL, Lang CC, Anker SD, Zannad F, Hung C, Sawhney JP, Naik A, Shimizu W, Hagiwara N, Wander GS, Anand I, Richards AM, Voors AA, Lam CS. Effects of combined renin–angiotensin–aldosterone system inhibitor and beta‐blocker treatment on outcomes in heart failure with reduced ejection fraction: insights from BIOSTAT‐CHF and ASIAN‐HF registries. Eur J Heart Fail 2020;22:1472-82. [DOI: 10.1002/ejhf.1869] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
104 Grote Beverborg N, van der Wal HH, Klip IT, Anker SD, Cleland J, Dickstein K, van Veldhuisen DJ, Voors AA, van der Meer P. Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies. JAMA Cardiol 2019;4:696-701. [PMID: 31188392 DOI: 10.1001/jamacardio.2019.1739] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
105 Colbert GB, Patel D, Lerma EV. Patiromer for the treatment of hyperkalemia. Expert Review of Clinical Pharmacology 2020;13:563-70. [DOI: 10.1080/17512433.2020.1774363] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
106 Verhestraeten C, Heggermont WA, Maris M. Clinical inertia in the treatment of heart failure: a major issue to tackle. Heart Fail Rev 2020. [PMID: 32474794 DOI: 10.1007/s10741-020-09979-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
107 Rossignol P, Williams B, Mayo MR, Warren S, Arthur S, Ackourey G, White WB, Agarwal R. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure. Eur J Heart Fail 2020;22:1462-71. [PMID: 32452085 DOI: 10.1002/ejhf.1860] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
108 Zhao J, Lei Y, Yang Y, Gao H, Gai Z, Li X. Metoprolol alleviates arginine vasopressin-induced cardiomyocyte hypertrophy by upregulating the AKT1-SERCA2 cascade in H9C2 cells. Cell Biosci 2020;10:72. [PMID: 32489586 DOI: 10.1186/s13578-020-00434-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
109 Linssen GCM, Veenis JF, Brunner-La Rocca HP, van Pol PEJ, Engelen DJM, van Tooren RM, Koornstra-Wortel HJJ, Hoes AW, Brugts JJ; CHECK-HF investigators. Differences in guideline-recommended heart failure medication between Dutch heart failure clinics: an analysis of the CHECK-HF registry. Neth Heart J 2020;28:334-44. [PMID: 32430655 DOI: 10.1007/s12471-020-01421-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
110 Sadiq AM, Chamba NG, Sadiq AM, Shao ER, Temu GA. Clinical Characteristics and Factors Associated with Heart Failure Readmission at a Tertiary Hospital in North-Eastern Tanzania. Cardiol Res Pract 2020;2020:2562593. [PMID: 32411443 DOI: 10.1155/2020/2562593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Goldgrab D, Balakumaran K, Kim MJ, Tabtabai SR. Updates in heart failure 30-day readmission prevention. Heart Fail Rev 2019;24:177-87. [PMID: 30488242 DOI: 10.1007/s10741-018-9754-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
112 Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res 2019;115:844-53. [PMID: 30715247 DOI: 10.1093/cvr/cvz035] [Cited by in Crossref: 66] [Cited by in F6Publishing: 88] [Article Influence: 33.0] [Reference Citation Analysis]
113 Shi C, van der Wal HH, Silljé HHW, Dokter MM, van den Berg F, Huizinga L, Vriesema M, Post J, Anker SD, Cleland JG, Ng LL, Samani NJ, Dickstein K, Zannad F, Lang CC, van Haelst PL, Gietema JA, Metra M, Ameri P, Canepa M, van Veldhuisen DJ, Voors AA, de Boer RA. Tumour biomarkers: association with heart failure outcomes. J Intern Med 2020;288:207-18. [PMID: 32372544 DOI: 10.1111/joim.13053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
114 Wang AY. Optimally managing hyperkalemia in patients with cardiorenal syndrome. Nephrol Dial Transplant 2019;34:iii36-44. [PMID: 31800079 DOI: 10.1093/ndt/gfz225] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
115 Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, Rosano GMC, Savarese G, Anker SD, Seferovic PM, Ruschitzka F, Coats AJS, Mebazaa A, McDonagh T, Sahuquillo A, Penco M, Maggioni AP, Lund LH; Heart Failure Long-Term Registry Investigators Group. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 2020;22:1378-89. [PMID: 32243669 DOI: 10.1002/ejhf.1793] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 25.5] [Reference Citation Analysis]
116 Spreafico M, Gasperoni F, Barbati G, Ieva F, Scagnetto A, Zanier L, Iorio A, Sinagra G, Di Lenarda A. Adherence to Disease-Modifying Therapy in Patients Hospitalized for HF: Findings from a Community-Based Study. Am J Cardiovasc Drugs 2020;20:179-90. [PMID: 31444666 DOI: 10.1007/s40256-019-00367-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
117 Mordi IR, Ouwerkerk W, Anker SD, Cleland JG, Dickstein K, Metra M, Ng LL, Samani NJ, van Veldhuisen DJ, Zannad F, Voors AA, Lang CC. Heart failure treatment up-titration and outcome and age: an analysis of BIOSTAT-CHF. Eur J Heart Fail 2021;23:436-44. [PMID: 32216000 DOI: 10.1002/ejhf.1799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
118 Kobayashi M, Stienen S, Ter Maaten JM, Dickstein K, Samani NJ, Lang CC, Ng LL, Anker SD, Metra M, Preud'homme G, Duarte K, Lamiral Z, Girerd N, Rossignol P, van Veldhuisen DJ, Voors AA, Zannad F, Ferreira JP. Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure. ESC Heart Fail 2020;7:953-63. [PMID: 32167681 DOI: 10.1002/ehf2.12634] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
119 Task force of the Hellenic Heart Failure Clinics Network. How to develop a national heart failure clinics network: a consensus document of the Hellenic Heart Failure Association. ESC Heart Fail 2020;7:15-25. [PMID: 32100972 DOI: 10.1002/ehf2.12558] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
120 Linssen GCM, Veenis JF, Kleberger A, Grosfeld MJW, Viergever EP, van Dalen BM, de Valk-Bedijn W, Langerveld J, Brunner-La Rocca HP, Hoes AW, Brugts JJ; CHECK-HF investigators. Medical treatment of octogenarians with chronic heart failure: data from CHECK-HF. Clin Res Cardiol 2020;109:1155-64. [PMID: 32030498 DOI: 10.1007/s00392-020-01607-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
121 Tromp J, Voors AA, Sharma A, Ferreira JP, Ouwerkerk W, Hillege HL, Gomez KA, Dickstein K, Anker SD, Metra M, Lang CC, Ng LL, van der Harst P, van Veldhuisen DJ, van der Meer P, Lam CSP, Zannad F, Sama IE. Distinct Pathological Pathways in Patients With Heart Failure and Diabetes. JACC Heart Fail 2020;8:234-42. [PMID: 32035890 DOI: 10.1016/j.jchf.2019.11.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 4.5] [Reference Citation Analysis]
122 Ter Maaten JM, Martens P, Damman K, Dickstein K, Ponikowski P, Lang CC, Ng LL, Anker SD, Samani NJ, Filippatos G, Cleland JG, Zannad F, Hillege HL, van Veldhuisen DJ, Metra M, Voors AA, Mullens W. Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. Clin Res Cardiol 2020;109:1048-59. [PMID: 32002631 DOI: 10.1007/s00392-020-01598-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
123 Lombardi CM, Ferreira JP, Carubelli V, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Voors A, Metra M. Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. Clin Res Cardiol 2020;109:967-77. [DOI: 10.1007/s00392-019-01588-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
124 Kovesdy CP, Gosmanova EO, Woods SD, Fogli JJ, Rowan CG, Hansen JL, Sauer BC. Real-world management of hyperkalemia with patiromer among United States Veterans. Postgraduate Medicine 2020;132:176-83. [DOI: 10.1080/00325481.2019.1706920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
125 Desai NR, Rowan CG, Alvarez PJ, Fogli J, Toto RD. Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization. PLoS One 2020;15:e0226844. [PMID: 31910208 DOI: 10.1371/journal.pone.0226844] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
126 Kadu M, Heckman GA, Stolee P, Perlman C. Risk of Hospitalization in Long-Term Care Residents Living with Heart Failure: a Retrospective Cohort Study. Can Geriatr J 2019;22:171-81. [PMID: 31885757 DOI: 10.5770/cgj.22.366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
127 Hoes MF, Tromp J, Ouwerkerk W, Bomer N, Oberdorf-Maass SU, Samani NJ, Ng LL, Lang CC, van der Harst P, Hillege H, Anker SD, Metra M, van Veldhuisen DJ, Voors AA, van der Meer P. The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach. Eur J Heart Fail 2020;22:2102-11. [PMID: 31797504 DOI: 10.1002/ejhf.1674] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
128 Brann A, Tran H, Greenberg B. Contemporary approach to treating heart failure. Trends Cardiovasc Med 2020;30:507-18. [PMID: 31901378 DOI: 10.1016/j.tcm.2019.11.011] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
129 Ancion A, Allepaerts S, Robinet S, Oury C, Pierard LA, Lancellotti P. Serum albumin level and long-term outcome in acute heart failure. Acta Cardiol 2019;74:465-71. [PMID: 30650026 DOI: 10.1080/00015385.2018.1521557] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
130 Lauder L, Ewen S, Emrich IE, Böhm M, Mahfoud F. [Cardiovascular pharmacotherapy and coronary revascularization in end-stage renal failure]. Herz 2019;44:611-29. [PMID: 31468075 DOI: 10.1007/s00059-019-04846-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
131 Lüscher TF. Optimizing heart failure management: anticoagulation, diuretic withdrawal, iron substitution, and novel inotropes. Eur Heart J 2019;40:3579-82. [PMID: 31750530 DOI: 10.1093/eurheartj/ehz847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
132 Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, Qin L. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom. J Am Heart Assoc 2019;8:e012655. [PMID: 31711387 DOI: 10.1161/JAHA.119.012655] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
133 Kobayashi M, Voors AA, Girerd N, Billotte M, Anker SD, Cleland JG, Lang CC, Ng LL, van Veldhuisen DJ, Dickstein K, Metra M, Duarte K, Rossignol P, Zannad F, Ferreira JP. Heart failure etiologies and clinical factors precipitating for worsening heart failure: Findings from BIOSTAT-CHF. Eur J Intern Med 2020;71:62-9. [PMID: 31708361 DOI: 10.1016/j.ejim.2019.10.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
134 Cao TH, Jones DJL, Voors AA, Quinn PA, Sandhu JK, Chan DCS, Parry HM, Mohan M, Mordi IR, Sama IE, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Lang CC, Ng LL. Plasma proteomic approach in patients with heart failure: insights into pathogenesis of disease progression and potential novel treatment targets. Eur J Heart Fail 2020;22:70-80. [PMID: 31692186 DOI: 10.1002/ejhf.1608] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
135 Rosenkranz S, Kramer T, Gerhardt F, Opitz C, Olsson KM, Hoeper MM. Pulmonary hypertension in HFpEF and HFrEF: Pathophysiology, diagnosis, treatment approaches. Herz 2019;44:483-90. [PMID: 31317203 DOI: 10.1007/s00059-019-4831-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
136 Lüscher TF. Heart failure with preserved ejection fraction: towards an understanding of an enigma. European Heart Journal 2019;40:3277-80. [DOI: 10.1093/eurheartj/ehz756] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
137 Coats AJS. Drug dosing for heart failure: does sex or size matter? Nat Rev Cardiol 2019;16:705-6. [PMID: 31628437 DOI: 10.1038/s41569-019-0298-7] [Reference Citation Analysis]
138 Lam CSP, Chandramouli C, Ahooja V, Verma S. SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects. J Am Heart Assoc. 2019;8:e013389. [PMID: 31607208 DOI: 10.1161/jaha.119.013389] [Cited by in Crossref: 57] [Cited by in F6Publishing: 78] [Article Influence: 19.0] [Reference Citation Analysis]
139 Whitley HP, Smith WD. Sex-based differences in medications for heart failure. The Lancet 2019;394:1210-2. [DOI: 10.1016/s0140-6736(19)31812-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
140 Zannad F, Rossignol P. Cardiorenal Syndrome Revisited. Circulation 2018;138:929-44. [PMID: 30354446 DOI: 10.1161/CIRCULATIONAHA.117.028814] [Cited by in Crossref: 87] [Cited by in F6Publishing: 117] [Article Influence: 29.0] [Reference Citation Analysis]
141 Canepa M, Franssen FME, Olschewski H, Lainscak M, Böhm M, Tavazzi L, Rosenkranz S. Diagnostic and Therapeutic Gaps in Patients With Heart Failure and Chronic Obstructive Pulmonary Disease. JACC Heart Fail 2019;7:823-33. [PMID: 31521680 DOI: 10.1016/j.jchf.2019.05.009] [Cited by in Crossref: 28] [Cited by in F6Publishing: 34] [Article Influence: 9.3] [Reference Citation Analysis]
142 Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P, Voors AA. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. J Am Coll Cardiol 2018;72:1081-90. [PMID: 30165978 DOI: 10.1016/j.jacc.2018.06.050] [Cited by in Crossref: 96] [Cited by in F6Publishing: 121] [Article Influence: 32.0] [Reference Citation Analysis]
143 Krittayaphong R, Laothavorn P, Hengrussamee K, Sanguanwong S, Kunjara-Na-Ayudhya R, Rattanasumawong K, Komoltri C, Sritara P; Thai ADHERE Registry Group. Ten-year survival and factors associated with increased mortality in patients admitted for acute decompensated heart failure in Thailand. Singapore Med J 2020;61:320-6. [PMID: 31489430 DOI: 10.11622/smedj.2019108] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
144 Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019;21:1169-1186. [PMID: 31129923 DOI: 10.1002/ejhf.1531] [Cited by in Crossref: 260] [Cited by in F6Publishing: 295] [Article Influence: 86.7] [Reference Citation Analysis]
145 Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP, Voors AA; ASIAN-HF investigators. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet 2019;394:1254-63. [PMID: 31447116 DOI: 10.1016/S0140-6736(19)31792-1] [Cited by in Crossref: 62] [Cited by in F6Publishing: 85] [Article Influence: 20.7] [Reference Citation Analysis]
146 Gracia E, Hamid A, Butler J. Timely Management of New-Onset Heart Failure: The Other Vulnerable Phase. Circulation 2019;140:621-3. [DOI: 10.1161/circulationaha.118.035452] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
147 Kimmoun A, Cotter G, Davison B, Takagi K, Addad F, Celutkiene J, Chioncel O, Solal AC, Diaz R, Damasceno A, Duengen HD, Filippatos G, Goncalvesova E, Merai I, Metra M, Ponikowski P, Privalov D, Sliwa K, Sani MU, Voors AA, Shogenov Z, Mebazaa A. Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. Eur J Heart Fail 2019;21:1459-67. [PMID: 31423712 DOI: 10.1002/ejhf.1575] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
148 Tromp J, Ferreira JP, Janwanishstaporn S, Shah M, Greenberg B, Zannad F, Lam CS. Heart failure around the world. Eur J Heart Fail 2019;21:1187-96. [DOI: 10.1002/ejhf.1585] [Cited by in Crossref: 21] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
149 Llubani R, Vukadinović D, Werner C, Marx N, Zewinger S, Böhm M. Hyperkalaemia in Heart Failure-Pathophysiology, Implications and Therapeutic Perspectives. Curr Heart Fail Rep 2018;15:390-7. [PMID: 30421355 DOI: 10.1007/s11897-018-0413-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
150 Berliner D, Hallbaum M, Bauersachs J. Current drug therapy for heart failure with reduced ejection fraction. Herz 2018;43:383-91. [PMID: 29777284 DOI: 10.1007/s00059-018-4712-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
151 Ouwerkerk W, Zwinderman AH, Ng LL, Demissei B, Hillege HL, Zannad F, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Ter Maaten JM, Lang CC, van der Harst P, Filippatos G, Dickstein K, Cleland JG, Anker SD, Voors AA. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. J Am Coll Cardiol 2018;71:386-98. [PMID: 29389354 DOI: 10.1016/j.jacc.2017.11.041] [Cited by in Crossref: 20] [Cited by in F6Publishing: 27] [Article Influence: 6.7] [Reference Citation Analysis]
152 Diamant MJ, Virani SA, MacKenzie WJ, Ignaszewski A, Toma M, Hawkins NM. Medical therapy doses at hospital discharge in patients with existing and de novo heart failure. ESC Heart Fail 2019;6:774-83. [PMID: 31218850 DOI: 10.1002/ehf2.12454] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
153 Wachter R, Senni M, Belohlavek J, Straburzynska-Migaj E, Witte KK, Kobalava Z, Fonseca C, Goncalvesova E, Cavusoglu Y, Fernandez A, Chaaban S, Bøhmer E, Pouleur AC, Mueller C, Tribouilloy C, Lonn E, A L Buraiki J, Gniot J, Mozheiko M, Lelonek M, Noè A, Schwende H, Bao W, Butylin D, Pascual-Figal D; TRANSITION Investigators. Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study. Eur J Heart Fail 2019;21:998-1007. [PMID: 31134724 DOI: 10.1002/ejhf.1498] [Cited by in Crossref: 88] [Cited by in F6Publishing: 110] [Article Influence: 29.3] [Reference Citation Analysis]
154 Papadimitriou L, Moore CK, Butler J, Long RC. The Limitations of Symptom-based Heart Failure Management. Card Fail Rev 2019;5:74-7. [PMID: 31179015 DOI: 10.15420/cfr.2019.3.2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
155 Maggioni AP. Appropriate prescriptions mean better outcomes: how can we improve ourselves? Eur J Heart Fail 2019;21:930-1. [PMID: 31099172 DOI: 10.1002/ejhf.1476] [Reference Citation Analysis]
156 Emmens JE, ter Maaten JM, Damman K, van Veldhuisen DJ, de Boer RA, Struck J, Bergmann A, Sama IE, Streng KW, Anker SD, Dickstein K, Lang CC, Metra M, Samani NJ, Ng LL, Voors AA. Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure. Circ: Heart Failure 2019;12. [DOI: 10.1161/circheartfailure.118.005544] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
157 Rossignol P, Hernandez AF, Solomon SD, Zannad F. Heart failure drug treatment. Lancet 2019;393:1034-44. [PMID: 30860029 DOI: 10.1016/S0140-6736(18)31808-7] [Cited by in Crossref: 99] [Cited by in F6Publishing: 123] [Article Influence: 33.0] [Reference Citation Analysis]
158 Sciatti E, Senni M, Lombardi CM, Gori M, Metra M. Sacubitril/valsartan: from a large clinical trial to clinical practice. J Cardiovasc Med (Hagerstown) 2018;19:473-9. [PMID: 29917003 DOI: 10.2459/JCM.0000000000000687] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
159 Higuchi S, Kohsaka S, Shiraishi Y, Katsuki T, Nagatomo Y, Mizuno A, Sujino Y, Kohno T, Goda A, Yoshikawa T. Association of renin-angiotensin system inhibitors with long-term outcomes in patients with systolic heart failure and moderate-to-severe kidney function impairment. European Journal of Internal Medicine 2019;62:58-66. [DOI: 10.1016/j.ejim.2019.01.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
160 Komajda M, Schöpe J, Wagenpfeil S, Tavazzi L, Böhm M, Ponikowski P, Anker SD, Filippatos GS, Cowie MR; QUALIFY Investigators. Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. Eur J Heart Fail 2019;21:921-9. [PMID: 30933403 DOI: 10.1002/ejhf.1459] [Cited by in Crossref: 42] [Cited by in F6Publishing: 53] [Article Influence: 14.0] [Reference Citation Analysis]
161 Ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, Ng LL, Dickstein K, Metra M, Samani NJ, Romaine SPR, Cleland J, Girerd N, Lang CC, van Veldhuisen DJ, Voors AA. Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail 2019;21:732-43. [PMID: 30843353 DOI: 10.1002/ejhf.1437] [Cited by in Crossref: 26] [Cited by in F6Publishing: 36] [Article Influence: 8.7] [Reference Citation Analysis]
162 Teng TK, Tromp J, Tay WT, Anand I, Ouwerkerk W, Chopra V, Wander GS, Yap JJ, MacDonald MR, Xu CF, Chia YM, Shimizu W, Richards AM, Voors A, Lam CS; ASIAN-HF investigators. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study. Lancet Glob Health 2018;6:e1008-18. [PMID: 30103979 DOI: 10.1016/S2214-109X(18)30306-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 65] [Article Influence: 17.7] [Reference Citation Analysis]
163 Bress AP, King JB. Optimizing Medical Therapy in Chronic Worsening HFrEF: A Long Way to Go. J Am Coll Cardiol 2019;73:945-7. [PMID: 30819363 DOI: 10.1016/j.jacc.2018.12.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
164 Peri-Okonny PA, Mi X, Khariton Y, Patel KK, Thomas L, Fonarow GC, Sharma PP, Duffy CI, Albert NM, Butler J, Hernandez AF, McCague K, Williams FB, DeVore AD, Patterson JH, Spertus JA. Target Doses of Heart Failure Medical Therapy and Blood Pressure: Insights From the CHAMP-HF Registry. JACC Heart Fail 2019;7:350-8. [PMID: 30738978 DOI: 10.1016/j.jchf.2018.11.011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 41] [Article Influence: 10.0] [Reference Citation Analysis]
165 Evans M, Palaka E, Furuland H, Bennett H, Linde C, Qin L, McEwan P, Bakhai A. The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrol 2019;20:31. [PMID: 30704421 DOI: 10.1186/s12882-019-1228-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
166 Dinatolo E, Sciatti E, Anker MS, Lombardi C, Dasseni N, Metra M. Updates in heart failure: what last year brought to us. ESC Heart Fail 2018;5:989-1007. [PMID: 30570225 DOI: 10.1002/ehf2.12385] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
167 Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, Palaka E, Bennett H, McEwan P. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail 2019;6:280-90. [PMID: 30629342 DOI: 10.1002/ehf2.12402] [Cited by in Crossref: 24] [Cited by in F6Publishing: 38] [Article Influence: 8.0] [Reference Citation Analysis]
168 Mordi IR, Santema BT, Kloosterman M, Choy AM, Rienstra M, van Gelder I, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Metra M, Ng LL, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Voors AA, Lang CC. Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. Clin Res Cardiol 2019;108:797-805. [PMID: 30610382 DOI: 10.1007/s00392-018-1409-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
169 Špinarová M, Špinar J, Pařenica J, Špinarová L, Málek F, Lábr K, Ludka O, Jarkovský J. Prescription and dosage of RAAS inhibitors in patients with chronic heart failure in the FAR NHL registry. Vnitř Lék 2019;65:13-8. [DOI: 10.36290/vnl.2019.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
170 Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P. Novel endotypes in heart failure: effects on guideline-directed medical therapy. European Heart Journal 2018;39:4269-76. [DOI: 10.1093/eurheartj/ehy712] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
171 Maggioni AP. Audits of clinical practice should be encouraged. Use of loop diuretics in patients without a diagnosis of heart failure should be discouraged. Eur J Prev Cardiol 2019;26:289-90. [PMID: 30509145 DOI: 10.1177/2047487318817075] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
172 Hu CS, Wu QH, Hu DY, Tkebuchava T. Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come. Chronic Dis Transl Med 2019;5:75-88. [PMID: 31367696 DOI: 10.1016/j.cdtm.2018.08.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
173 Cao TH, Jones DJL, Quinn PA, Chan DCS, Hafid N, Parry HM, Mohan M, Sandhu JK, Anker SD, Cleland JG, Dickstein K, Filippatos G, Hillege HL, Metra M, Ponikowski P, Samani NJ, Van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, Lang CC, Ng LL. Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clin Proteomics 2018;15:35. [PMID: 30410428 DOI: 10.1186/s12014-018-9213-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
174 Ferreira JP, Metra M, Mordi I, Gregson J, ter Maaten JM, Tromp J, Anker SD, Dickstein K, Hillege HL, Ng LL, van Veldhuisen DJ, Lang CC, Voors AA, Zannad F. Heart failure in the outpatient versus inpatient setting: findings from the BIOSTAT-CHF study: HF outpatients versus inpatients. Eur J Heart Fail 2019;21:112-20. [DOI: 10.1002/ejhf.1323] [Cited by in Crossref: 23] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
175 Burgon TB, Cox-Chapman J, Czarnecki C, Kropp R, Guerriere R, Paculdo D, Peabody JW. Engaging Primary Care Providers to Reduce Unwanted Clinical Variation and Support ACO Cost and Quality Goals: A Unique Provider-Payer Collaboration. Popul Health Manag 2019;22:321-9. [PMID: 30328782 DOI: 10.1089/pop.2018.0111] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
176 Chiu MH, Miller RJH, Barry R, Li B, Har BJ, Wilton SB, Knudtson M, Howlett JG, James MT. Kidney Function, ACE-Inhibitor/Angiotensin Receptor Blocker Use, and Survival Following Hospitalization for Heart Failure: A Cohort Study. Can J Kidney Health Dis 2018;5:2054358118804838. [PMID: 30349729 DOI: 10.1177/2054358118804838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
177 Lazarova M, Lazar D, Malek F, Vaclavik J, Taborsky M, Ignaszewski A. Heart failure disease management program, its contribution to established pharmacotherapy and long-term prognosis in real clinical practice - retrospective data analysis. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2019;163:318-23. [PMID: 30305762 DOI: 10.5507/bp.2018.059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
178 Atherton JJ, Sindone A, De Pasquale CG, Driscoll A, Macdonald PS, Hopper I, Kistler PM, Briffa T, Wong J, Abhayaratna W, Thomas L, Audehm R, Newton P, O'loughlin J, Branagan M, Connell C. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: Guidelines for the Prevention, Detection, and Management of Heart Failure in Australia 2018. Heart, Lung and Circulation 2018;27:1123-208. [DOI: 10.1016/j.hlc.2018.06.1042] [Cited by in Crossref: 122] [Cited by in F6Publishing: 152] [Article Influence: 30.5] [Reference Citation Analysis]
179 Ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Navis G, Ng L, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, de Borst MH. Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. Int J Cardiol 2018;253:84-90. [PMID: 29306478 DOI: 10.1016/j.ijcard.2017.10.010] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 7.8] [Reference Citation Analysis]
180 Bakhai A, Palaka E, Linde C, Bennett H, Furuland H, Qin L, McEwan P, Evans M. Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure. J Med Econ 2018;21:1172-82. [PMID: 30160541 DOI: 10.1080/13696998.2018.1518239] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
181 Furuland H, McEwan P, Evans M, Linde C, Ayoubkhani D, Bakhai A, Palaka E, Bennett H, Qin L. Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC Nephrol 2018;19:211. [PMID: 30134846 DOI: 10.1186/s12882-018-1007-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
182 Streng KW, Voors AA, Hillege HL, Anker SD, Cleland JG, Dickstein K, Filippatos G, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Damman K, van der Meer P, Lang CC. Waist-to-hip ratio and mortality in heart failure: Waist-to-hip ratio and mortality in HF. Eur J Heart Fail 2018;20:1269-77. [DOI: 10.1002/ejhf.1244] [Cited by in Crossref: 49] [Cited by in F6Publishing: 51] [Article Influence: 12.3] [Reference Citation Analysis]
183 Greene SJ, Butler J, Albert NM, Devore AD, Sharma PP, Duffy CI, Hill CL, Mccague K, Mi X, Patterson JH, Spertus JA, Thomas L, Williams FB, Hernandez AF, Fonarow GC. Medical Therapy for Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology 2018;72:351-66. [DOI: 10.1016/j.jacc.2018.04.070] [Cited by in Crossref: 290] [Cited by in F6Publishing: 378] [Article Influence: 72.5] [Reference Citation Analysis]
184 Maggioni AP. Smartphones, barbershops, and pharmacists to improve adherence to drug treatment in chronic cardiovascular conditions: the end justifies all the means. Eur J Heart Fail 2018;20:1360-2. [PMID: 29896931 DOI: 10.1002/ejhf.1242] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
185 Wintrich J, Kindermann I, Böhm M. [Update on heart failure]. Herz 2020;45:158-69. [PMID: 29869700 DOI: 10.1007/s00059-018-4715-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
186 Weir MR, Bushinsky DA, Benton WW, Woods SD, Mayo MR, Arthur SP, Pitt B, Bakris GL. Effect of Patiromer on Hyperkalemia Recurrence in Older Chronic Kidney Disease Patients Taking RAAS Inhibitors. The American Journal of Medicine 2018;131:555-564.e3. [DOI: 10.1016/j.amjmed.2017.11.011] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
187 Pitt B, Garza D. The tolerability and safety profile of patiromer: a novel polymer-based potassium binder for the treatment of hyperkalemia. Expert Opin Drug Saf 2018;17:525-35. [PMID: 29667438 DOI: 10.1080/14740338.2018.1462335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
188 Lüscher TF. Novel insights in HFpEF, cardiomyopathies, and myocarditis. Eur Heart J 2018;39:819-22. [PMID: 29522219 DOI: 10.1093/eurheartj/ehy105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
189 Bhat S, Kansal M, Kondos GT, Groo V. Outcomes of a Pharmacist-Managed Heart Failure Medication Titration Assistance Clinic. Ann Pharmacother 2018;52:724-32. [DOI: 10.1177/1060028018760568] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
190 Pitt B, Bushinsky DA, Kitzman DW, Ruschitzka F, Metra M, Filippatos G, Rossignol P, Du Mond C, Garza D, Berman L, Lainscak M; Patiromer-204 Investigators. Evaluation of an individualized dose titration regimen of patiromer to prevent hyperkalaemia in patients with heart failure and chronic kidney disease. ESC Heart Fail 2018;5:257-66. [PMID: 29369537 DOI: 10.1002/ehf2.12265] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 8.0] [Reference Citation Analysis]
191 Tamargo J, Caballero R, Delpón E. New Therapeutic Approaches for the Treatment of Hyperkalemia in Patients Treated with Renin-Angiotensin-Aldosterone System Inhibitors. Cardiovasc Drugs Ther 2018;32:99-119. [DOI: 10.1007/s10557-017-6767-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
192 Beusekamp JC, Tromp J, van der Wal HH, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Rossignol P, Zannad F, Voors AA, van der Meer P. Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. Eur J Heart Fail 2018;20:923-30. [PMID: 29327797 DOI: 10.1002/ejhf.1079] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
193 Lund LH, Køber L, Swedberg K, Ruschitzka F. The year in cardiology 2017: heart failure. European Heart Journal 2018;39:832-9. [DOI: 10.1093/eurheartj/ehx782] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
194 Wurm R, Huelsmann M, Hienert M, Seidl V, Wiedemann D, Laufer G, Kocher A, Adlbrecht C, Andreas M. Quality of medical therapy in heart failure patients undergoing elective revascularisation: A protective effect of disease modifying therapy at discharge. Sci Rep 2017;7:14909. [PMID: 29097746 DOI: 10.1038/s41598-017-15004-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
195 Bayes-genis A, Núñez J, Zannad F, Ferreira JP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Metra M, Lupón J, Voors AA. The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. Journal of the American College of Cardiology 2017;70:2128-36. [DOI: 10.1016/j.jacc.2017.08.057] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
196 Lüscher TF. Risk factors for chronic heart failure: obesity, renal dysfunction, arteriovenous fistulas, and amyloid deposition. European Heart Journal 2017;38:1857-60. [DOI: 10.1093/eurheartj/ehx323] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
197 Tavazzi L. Observational research as a platform for evidence-based public health policies and learning health systems. Eur Heart J 2017;38:1891-4. [PMID: 28379426 DOI: 10.1093/eurheartj/ehx113] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
198 Cai L, Fan G, Wang F, Liu S, Li T, Cong X, Chun J, Chen X. Protective Role for LPA3 in Cardiac Hypertrophy Induced by Myocardial Infarction but Not by Isoproterenol. Front Physiol 2017;8:356. [PMID: 28611684 DOI: 10.3389/fphys.2017.00356] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
199 Komajda M, Cowie MR, Tavazzi L, Ponikowski P, Anker SD, Filippatos GS; on behalf of the QUALIFY Investigators. Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry: Guideline adherence and outcomes in heart failure: QUALIFY. Eur J Heart Fail 2017;19:1414-23. [DOI: 10.1002/ejhf.887] [Cited by in Crossref: 119] [Cited by in F6Publishing: 118] [Article Influence: 23.8] [Reference Citation Analysis]
200 Cowie MR, Komajda M. Quality of Physician Adherence to Guideline Recommendations for Life-saving Treatment in Heart Failure: an International Survey. Card Fail Rev 2017;3:130-3. [PMID: 29387466 DOI: 10.15420/cfr.2017:13:1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
201 Yao YN, Zhang RC, An T, Zhang Q, Zhao XK, Zhang J. Different prognostic association of systolic blood pressure at different time points with postdischarge events in patients hospitalized for decompensated heart failure. J Geriatr Cardiol 2019;16:676-88. [PMID: 31645853 DOI: 10.11909/j.issn.1671-5411.2019.09.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]